Empagliflozin selected cardiovascular and safety outcomes in routine care: First results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

被引：0
|
作者：
Patorno, E. [1 ]
Pawar, A. [1 ]
Franklin, J. M. [1 ]
Najafzadeh, M. [1 ]
Deruaz-Luyet, A. [2 ]
Brodovicz, K. G. [3 ]
Sambevski, S. [4 ]
Bessette, L. G. [1 ]
Kulldorff, M. [1 ]
Schneeweiss, S. [1 ]
机构：
[1] Harvard Med Sch, Div Pharmacoepidemiol, Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Boehringer Ingelheim Int GmbH, Corp Dept Global Epidemiol, Ingelheim, Germany
[3] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[4] Boehringer Ingelheim Int GmbH, Corp Dept Med, Ingelheim, Germany
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2020年 / 104卷
关键词：
Sodium glucose co-transport inhibitor 2; Healthcare utilization; Diabetic ketoacidosis;
D O I：
10.1016/j.metabol.2019.12.072
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Empagliflozin and the risk of heart failure hospitalization, heart failure worsening and hospital readmission in routine clinical care: interim results from the EMPRISE study
    Patorno, E.
    Pawar, A. Ajinkya
    Najafzadeh, M.
    Deruaz-Luyet, A.
    Brodovicz, K.
    Vedin, O.
    Gautam, N.
    Schneeweiss, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 287 - 288
  • [42] Empagliflozin on the risk of retinopathy in patients with type 2 diabetes: Results from the EMPRISE study
    Tesfaye, Helen
    Htoo, Phyo Than T.
    Paik, Julie M.
    Zakoul, Heidi
    Schmedt, Niklas
    Deruaz-Luyet, Anouk
    Koeneman, Lisette
    Wexler, Deborah
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 15 - 15
  • [43] Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study
    Engstrom, Arvid
    Soderling, Jonas
    Hviid, Anders
    Eliasson, Bjorn
    Gudbjornsdottir, Soffia
    Wintzell, Viktor
    Hveem, Kristian
    Jonasson, Christian
    Melbye, Mads
    Pasternak, Bjorn
    Ueda, Peter
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (05) : 432 - 443
  • [44] Comparative Cardiovascular and Renal Effectiveness of Empagliflozin and Dapagliflozin: Scandinavian Cohort Study
    Engstrom, Arvid
    Soderling, Jonas
    Hviid, Anders
    Eliasson, Bjorn
    Gudbjornsdottir, Soffia
    Wintzell, Viktor
    Hveem, Kristian
    Jonasson, Christian
    Melbye, Mads
    Pasternak, Bjorn
    Ueda, Peter
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 87 - 88
  • [45] Empagliflozin on the Risk of Retinopathy in Patients with Type 2 Diabetes-Results from the EMPRISE Study
    Tesfaye, Helen
    Htoo, Phyo T.
    Paik, Julie M.
    Zakoul, Heidi
    Schmedt, Niklas
    Deruaz-Luyet, Anouk
    Koeneman, Lisette
    Wexler, Deborah J.
    Patorno, Elisabetta
    DIABETES, 2023, 72
  • [46] HEALTHCARE RESOURCE UTILIZATION IN PATIENTS TREATED WITH EMPAGLIFLOZIN IN EAST ASIA: RESULTS FROM EMPRISE STUDY
    Sheu, Wayne
    Seino, Yutaka
    Tan, Elise
    Yabe, Daisuke
    Ha, Kyoung Hwa
    Chung, Wook-Jin
    Taneda, Yusuke
    Lei, Wei-Yu
    Ustyugova, Anastasia
    Klement, Riho
    Deruaz-Luyet, Anouk
    Kyaw, Moe
    Kim, Dae Jung
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1470 - 1470
  • [47] Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care
    Desai, Rishi J.
    Glynn, Robert J.
    Everett, Brendan M.
    Schneeweiss, Sebastian
    Wexler, Deborah J.
    Bessette, Lily G.
    Deruaz-Luyet, Anouk
    Vedin, Ola
    Brodovicz, Kimberly
    Patorno, Elisabetta
    AMERICAN HEART JOURNAL, 2022, 254 : 203 - 215
  • [48] Cardiovascular effectiveness of empagliflozin versus glucagon-like peptide-1 receptor agonists or liraglutide in the emprise study
    Htoo, Phyo
    Tesfaye, Helen
    Paik, Julie
    Wexler, Deborah
    Najafzadeh, Mehdi
    Glynn, Robert
    Deruaz-Luyet, Anouk
    Farsani, Soulmaz
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 99 - 100
  • [49] COMPARATIVE CARDIOVASCULAR SAFETY AND EFFECTIVENESS OF LINAGLIPTIN IN ROUTINE CARE: AN INTERIM ANALYSIS FROM A MONITORING PROGRAM
    Patorno, Elisabetta
    Gopalakrishnan, Chandrasekar
    Bartels, Dorothee B.
    Brodovicz, Kimberly G.
    Meyers, Andrea
    Barberio, Julie
    Liu, Jun
    Schneeweiss, Sebastian
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 167 - 167
  • [50] Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study
    Langslet, Gisle
    Nystroem, Thomas
    Vistisen, Dorte
    Carstensen, Bendix
    Grip, Emilie Toresson
    Casajust, Paula
    Tskhvarashvili, Giorgi
    Hoti, Fabian
    Klement, Riho
    Karlsdotter, Kristina
    Tuovinen, Mikko
    Ofstad, Anne Pernille
    Lajer, Maria
    Shay, Christina
    Koeneman, Lisette
    Farsani, Soulmaz Fazeli
    Niskanen, Leo
    Halvorsen, Sigrun
    JOURNAL OF DIABETES RESEARCH, 2024, 2024
12345